updated efficacy and safety results of the phase 3 candor study
Published 3 years ago • 550 plays • Length 4:32Download video MP4
Download video MP3
Similar videos
-
12:47
efficacy and safety of kdd in rrmm: cross‐study comparison of candor and mmy1001
-
3:53
updated efficacy and safety from anchor (op-104) study of melflufen
-
3:49
primary analysis results from the randomized, open-label, phase 3 study candor
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
17:24
dr. paul g. richardson provides study updates on the phase 3 determination trial for ndmm patients
-
8:33
initial safety results for phase 2 magnetismm-3 trial presented at asco 2022
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
2:35
safety and efficacy of once-weekly carfilzomib dosing in frail patients: phase 3 arrow
-
3:06
what is the candor trial?
-
3:52
is dara being used in the frontline setting for myeloma patients?
-
15:30
overall survival results in transplant-ineligible newly diagnosed mm pts: phase 3 maia study
-
5:38
post-hoc analysis of efficacy and safety in the swog s0777 trial stratified by age
-
6:36
candor results reveal new regimen for rrmm: kdd
-
9:01
updated results of bcma/cd19 dual-targeting fast car-t gc012f dual-targeting car-t in rrmm
-
3:40
are four-drug combinations more effective than three-drug combinations?
-
2:09
the candor trial extended follow-up: daratumumab for r/r myeloma
-
2:14
dreamm-5 study of blenrep (belantamab mafodotin) combined with nirogacestat in rrmm patients
-
7:02
talquetamab in pts with relapsed/refractory multiple myeloma: phase 1/2 results from monumental-1
-
2:36
efficacy and safety of daratumumab, bortezomib, and dex (d-vd) vs vd in first relapse patients